New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Enabling a new era in minimally invasive obesity treatment across Europe
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Subscribe To Our Newsletter & Stay Updated
